These data were presented at the 2010 ACVIM Forum, Anaheim, CA
The Effect of Intravenous Lidocaine Infusion on Bronchoalveolar Lavage Cytology in Equine Recurrent Airway Obstruction
Article first published online: 1 NOV 2012
Copyright © 2012 by the American College of Veterinary Internal Medicine
Journal of Veterinary Internal Medicine
Volume 26, Issue 6, pages 1427–1432, November/December 2012
How to Cite
Wilson, M.E., Berney, C., Behan, A.L. and Robinson, N.E. (2012), The Effect of Intravenous Lidocaine Infusion on Bronchoalveolar Lavage Cytology in Equine Recurrent Airway Obstruction. Journal of Veterinary Internal Medicine, 26: 1427–1432. doi: 10.1111/j.1939-1676.2012.01010.x
- Issue published online: 20 NOV 2012
- Article first published online: 1 NOV 2012
- Manuscript Accepted: 20 AUG 2012
- Manuscript Revised: 16 JUL 2012
- Manuscript Received: 9 APR 2012
- Matilda Wilson endowment
- BALF ;
- Lidocaine hydrochloride;
Lidocaine decreases neutrophilic inflammation in models of acute lung injury and decreases inflammation in asthmatic patients. Neutrophilic bronchiolitis develops in recurrent airway obstruction (RAO), but it remains unknown if lidocaine infusion decreases neutrophil migration into the airways.
Lidocaine decreases neutrophilic inflammation as measured in BALF in RAO-affected horses.
Six RAO-susceptible horses in remission.
In a randomized cross-over design, horses received lactated Ringer's solution (LRS) IV or lidocaine hydrochloride IV with a minimum of 4 weeks at pasture between treatments. Treatments were delivered as continuous infusions beginning 4 hours before and for 68 hours during exposure to hay and straw challenge. Clinical score (CS, grade 0–8), maximal change in pleural pressure (∆Pplmax), and bronchoalveolar lavage fluid (BALF) cytology were measured at baseline and the end of challenge (day 4). Plasma lidocaine concentrations were monitored daily.
At baseline, there were no significant differences in variables between treatments. Plasma lidocaine concentration was consistently > 1100 ng/mL. After challenge, CS increased significantly [baseline: 2/8 (2–3), [median (interquartile range)]; day 4: 4/8 (4–5) P = .0006] as did ∆Pplmax [baseline: 3.6 (2.63–4.95) cmH20; day 4: 9.62 (6.5–16) P = .0036], but there was no difference between treatments. Percentage of neutrophils was not different between treatments, but lidocaine infusion significantly increased BALF total cells [baseline: LRS 2.18 ± 0.82 × 105 cells/mL (mean ± SD), lidocaine 1.6 ± 0.3 × 105, day 4: LRS 2.0 ± 0.88 × 105, lidocaine 4.4 ± 2 × 105 (P = .0045)].
Conclusions and Clinical Importance
Lidocaine does not decrease neutrophilic inflammation in RAO.